In chronic lymphocytic leukemia (CLL), spontaneous regressions are an exceptional phenomenon, whose biologic features are unknown. We describe 9 CLL patients who underwent a spontaneous clinical regression over an 11-year follow-up, in spite of a residual neoplastic clone detected by flow cytometry. CD38 and ZAP-70 were negative in all cases. Immunoglobulin heavy chain variable region (IgVH) genes, mutated in all 7 evaluable patients, were restricted to the VH3 family in 6, with the usage of V H 3-30 gene in 2. The light chain variable region genes were mutated in 6/8 cases, with the usage of V κ 4-1 gene in 3. Microarray analysis of CLL cells revealed a distinctive genomic profile with an overrepresentation of BCR-related and ribosomal genes, regulators of signal transduction and transcription. The number of activated T lymphocytes expressing IFN-γ, TNF-α and IL-4 was similar between CLL in spontaneous regression and healthy individuals. In conclusion, spontaneous clinical regressions can occur in CLL despite the persistence of the neoplastic clone and the biologic features include negative CD38 and ZAP-70, mutated
Introduction
Chronic lymphocytic leukemia (CLL) is a B-cell disorder with a variable natural history and prognosis. More than half of the patients at diagnosis show an early stage of the disease.
The median overall survival for this group of patients is about 10 years 1,2 . They normally undergo clinical observation up to disease progression and treatment requirement. The interval from diagnosis to progression is extremely variable in duration, lasting from few months to decades. Different biologic parameters recently identified allow to predict at diagnosis the time to progression and survival in this group of patients 3, 4 .
We have previously reported on the unique biologic profile displayed by a group of patients with highly stable disease for more than 10 years 5, 6 , characterized by a typical morphology and immunophenotype, a normal T-cell subset distribution and normal serum immunoglobulin (Ig) levels, lack of CD38 expression, absence of poor prognosis genetic markers or p53 abnormalities, and a mutated profile of the Ig heavy chain variable region (VH) genes, with no Ig VH3-21 involvement 5 . One fourth of highly stable CLL utilized the VH3-72 gene and, in some cases, expressed VH and light chain variable region (VL) sequences with homologous third complementarity-determing region (CDR3s), suggesting recognition of a common antigen 6 .
The occurrence of a spontaneous regression of CLL in the absence of any previous treatment is exceptional. In the literature, there are only few papers in which this phenomenon has been reported [7] [8] [9] [10] [11] . The clinical features of these cases have been described, but there is no information on the biologic markers of their disease or on the pathogenesis of this event. Particularly, it is not known whether there are distinctive features which can identify among patients with good prognosis those who may experience over time a spontaneous regression of their disease. Moreover, it is interesting to note that such an event can occur also in patients with trisomy 12 9 .
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From In the present study, we describe 9 patients with CLL followed at our Institution, in which the occurrence of a spontaneous clinical regression has been observed over a period of 3 to 28 years from diagnosis and who underwent an extended biologic evaluation of the disease.
Patients and Methods

Patients and samples
Spontaneous regression was defined as the achievement of a clinical regression of the disease (i.e. absence of lymphadenopathy, splenomegaly or constitutional symptoms; peripheral lymphocytosis less than 4 x 10 9 /L, no anemia, no thrombocytopenia) in the absence of any previous treatment. As no bone marrow (BM) assessment of CLL infiltration was performed, we could not evaluate the occurrence of a clinical remission.
All patients, 3 males and 6 females, were diagnosed and followed at the Institute of Hematology, "Sapienza" University of Rome. At the time of diagnosis, the median age was 53 years (range 41-73). The proportion of circulating lymphocytes was 68% (64-90%) of the white blood cells (WBC), with a median lymphocyte count of 11.8 x 10 9 /L (8.7-27.6), 78% of which was represented by CLL cells (range 65-82%). Clinical stage according to Binet' s and Rai's classifications 1, 2 was A/0 in 7 and A/II in 2 cases, who presented a mild splenomegaly (longitudinal diameter, 13 cm). Following diagnosis, patients were seen at our Institution every 3 months during the first year, every 4 months during the second year, every 6 months during the third year and subsequently once a year.
Over the years, the disease remained stable and no treatment requirement occurred. A progressive and gradual decrease in the lymphocyte count was observed over time.
Median time from the highest lymphocyte count reached to the first lymphocyte count below 4 x 10 9 /L was 9 years (range 3-24 years). Thus, after a median follow-up of 11 years (range: 3-28) from diagnosis, a clinical spontaneous regression of the disease For personal use only. on October 3, 2017. by guest www.bloodjournal.org From occurred. This phenomenon has remained stable and the study was performed after a median follow-up of 16 years (range: 3-29) from diagnosis; at this time, the median lymphocyte count was 3.16 x 10 9 /L (1.3-4.0) and the median percentage of lymphocytes was 43% (30-53%) ( Figure 1 ). The hemoglobin level and platelet counts remained within the normal range. No enlarged nodes or splenomegaly were detected by physical examination and abdominal ultrasound. The clinical features of the patients are summarized in Table 1 .
All patients but one (#9) underwent peripheral blood (PB) sampling after giving their informed consent according to the Declaration of Helsinki for the blood collection and biologic analyses included in the present study, which was approved by the Institutional Review Board of the Department of Cellular Biotechnologies and Hematology, "Sapienza" University, Rome. The regression persisted thereafter, as all patients have remained in persistent regression after an updated follow-up of 16 years (5-31), with the exception of case #9, who showed a lymphocyte count of 5.2 x 10 9 /L at the last visit.
PB cells count, morphology and immunophenotype
The PB counts were analyzed using the H3 and ADVIA instruments (Bayer, Milan, Italy).
The morphologic observation was carried out on May-Grunwald/Giemsa-stained PB films. 
Samples purification
Highly purified CD19+ cells (>98%) were obtained from PB mononuclear cells by standard positive selection using an anti-CD19 antibody conjugated with magnetic beads (Miltenyi Biotech, Auburn, CA) and were used for IgVH mutation and microarray study. For the latter, samples with at least 95% of CD5+/CD19+ clonal cells after purification were selected. The CD19 negative fraction was cryopreserved in the presence of DMSO (10%) in liquid nitrogen and subsequently utilized to evaluate T-cell cytokine production.
PCR amplification of immunoglobulin rearrangements and sequence analysis
Genomic DNA was extracted from leukemic cells using Wizard Genomic DNA Purification kit (Promega Corp., Madison, WI) according to the manufacturer's instructions. IgHV-D-J, IgKV-J and IgLV-J gene rearrangements were amplified by polymerase chain reaction (PCR) from genomic DNA using Taq polymerase with family-specific primes hybridizing to leader or framework (FR) 1 sequences and J H , J k or J λ , as previously described 12 Sequences were considered unmutated if deviation from the closest germline gene was < 2%.
Analyses of HCDR3 and LCDR3 rearrangements
Heavy chain third complementarity-determing region (HCDR3) length was determined according to Kabat et al. 13 by counting the number of amino acids between position H94 at the 3' end of FR3 (usually two amino acids downstream of the conserved cysteine) and position H102 at the beginning of FR4 (a conserved tryptophan in all JH segments).
The length of V L CDR3 was determined by counting the number of amino acids between position L89 (preceded by a conserved cysteine) at the end of FR3 and the position L97 at the beginning of FR4 (a conserved phenylalanine in all in all JL segments). Total RNA was extracted using the TRIzol reagent (Gibco BRL, Grand Island, NY). To assess RNA quality, 2 µl of RNA from each sample were analyzed by electrophoresis on agarose gel containing 10 mg/ml ethidium bromide (SIGMA-ALDRICH, St. Louis, MO); for all samples, the 260/280 ratio was >1.8, as required for microarray analysis. For oligonucleotide array analysis, the HGU133A.2 arrays were used. The detailed protocol for For personal use only. on October 3, 2017. by guest www.bloodjournal.org From sample preparation and microarray processing is available from Affymetrix (www.affymetrix.com). For statistical analysis, Affymetrix gene expression data were processed with dChip software, (www.dchip.org), which uses an invariant set normalization method. The array with the median overall intensity was chosen as the baseline for normalization. Model based expressions were computed for each array and probe set, using the PM-MM model 14 . For unsupervised analysis, the following nonspecific filtering criteria were used: 1) gene expression levels were required to be higher than 300 in at least 10% of the samples; 2) the ratio of the standard deviation to the mean expression across all samples was required to be between 0.5 and 1000. To compare the 4 samples with spontaneous regression analyzed vs the remaining IgVH mutated cases, a t-test was used; only the genes with a p-value <0.05 and a fold change >1.5 were retained. Furthermore, to compare patients with a different clinical scenario -namely spontaneous regression, stable disease and progressive disease -an ANOVA was applied with a p <0.001. The microarray data has been deposited in GEO under the accession number GSE15777.
Microarray preparation and data analysis
Intracellular T-cell cytokine expression analysis
Circulating lymphocytes from CLL patients in spontaneous regression (n=6), CLL with stable disease (n=5, 2 unmutated IgVH and 3 mutated IgVH) and with progressive disease 
Statistical analysis
Differences between series of continuous and discrete variables were evaluated for significance by the Student t-test and Chi-square/Fisher's exact test, respectively.
Results
PB morphology and immunophenotype
Morphologically, lymphocytes were mostly small-size with a proportion of large granular lymphocytes (LGL) that varied from 0 to 35% (median 17%).
Immunophenotype documented a variable proportion of clonal B cells, that ranged between 3 and 63% (median 44%) of total lymphocytes: they were positive for CD5, CD23, CD19, CD20, negative for CD79b, FMC-7 (5 out of 6), CD18 and CD11a (5 out of 6), with κ light chain restriction in 6 cases and λ light chain restriction in 3. Therefore, CLL cells showed a typical phenotype, with a Matutes' immunophenotypic score of 4-5 in all cases.
CD38 on B lymphocytes was less than 7% in all cases, ranging from 0 to 6% (median 1.5%). ZAP-70 RNA expression levels were low, as defined by quantitative PCR on CD19enriched lymphocytes (data not shown).
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From Residual normal B-cells represented 0.3 to 5% of total lymphocytes and 0.4 to 57% of CD19+ lymphocytes. The proportion of T-cells ranged from 26 to 72% and NK cells from 1 to 21%. The CD4/CD8 ratio was normal in all but one case, ranging from 1.2 to 3.25 (median 1.8) ( Table 2 ). The PB immunophenotype was evaluated during the course of the disease in cases #1, #2 and #6, showing a slowly progressive reduction of the CLL clone over time.
Molecular analysis of Ig gene rearrangements
Productive IgVH-D-J were successfully amplified and sequenced in 7 patients. Using a cut-off value of ≥ 2% mutation rate, all 7 proved mutated with a mean mutation frequency of 7.2% ± 2.8 (median 7.4%, range 2.7-10.7%). Interestingly, all patients but 1 showed an involvement of the V H 3 family. The mean sequence length of the light complementarity-determining region 3 (LCDR3) was 10.7 ± 0.7 codons (Table 3) .
Microarray analysis
Unsupervised analysis of all 22 CLL samples, including 4 with spontaneous regression revealed a tight clustering of the latter (Figure 2 ), suggesting that these cases have a common genetic signature, distinct from the remaining cases, that is already evident when using unbiased filtering criteria. To identify specifically expressed genes in the spontaneous regression cases, different approaches were used. First, a t-test was used to compare these cases (n=4) with the remaining IgVH mutated cases (n=12); we chose to exclude IgVH unmutated patients, as well as those cases whose mutational status was unknown, because they could provide misleading results. This analysis selected 204 genes differentially expressed in these cases; again, the spontaneous regression patients Among the genes consistently upregulated in both spontaneous regression and stable disease patients it was possible to identify WWP1, known to regulate p53 stability, BPTF, which regulates apoptosis, RBP2, which participates to cell cycle control through its direct interaction with pRb, and DICER. Of interest, the BCR signaling pathway is overrepresented, being, in general, more highly expressed in cases with spontaneous regression and stable disease; similarly, genes involved in the regulation of transcription are upregulated in these two subsets of patients.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From Among the downregulated genes in both spontaneous regression and stable disease cases, it is worth mentioning DUSP1, a phosphatase specific of the MAPK pathway, which plays a role in apoptosis induction, GADD34, known to be involved in melanoma progression; at variance, NOL1 and SERTAD2, which are specifically expressed during the S phase, together with POLR2I and CREG1, which are involved in regulation of transcription, were specifically downregulated in spontaneous regression cases. A detailed gene list is provided in Table 4 .
Furthermore, we compared the gene profile of this CLL cohort to that of circulating B lymphocytes from healthy donors. In the unsupervised analysis, CLL in spontaneous regression clustered with normal B lymphocytes (data not shown). To further explore this similarity, we analyzed the expression of the genes selected by ANOVA also on normal B lymphocytes; as already observed by unsupervised analysis, this approach highlighted a closer similarity between CLL in spontaneous regression and lymphocytes from healthy donors (Supplementary figure 1) .
Intracellular T-cell cytokine expression
No significant differences were observed between CLL in spontaneous regression and normal individuals in the absolute number of activated T lymphocytes expressing cytoplasmic IFN-γ, TNF-α and IL-4 (Table 5 ). Furthermore, we compared the absolute number of T-cells expressing IFN-γ, TNF-α and IL-4 between patients in different phases of the disease, as shown in Table 5 . CD3+ cells from progressive CLL expressed more IFN-γ than CLL in spontaneous regression, stable CLL and control donors, but the difference was not statistically significant except for control donors (p=0.013). In contrast, a statistically significant increase in the number of TNF-α expressing T-cells was found in progressive CLL compared to CLL in spontaneous regression (p=0.001), stable CLL For personal use only. on October 3, 2017. by guest www.bloodjournal.org From (p=0.011) and healthy individuals (p=0.000). Finally, the number of CD3+ cells that expressed IL-4 was similar in all groups studied.
Discussion
In CLL, the occurrence of spontaneous regression of the disease is an exceptional event.
Recognized since the seventies 16, 17 , this phenomenon has been rarely described in the literature. In the largest series of spontaneous regressions 10 , as well as in smaller series from other groups, no exhaustive data on the biologic features of the disease are reported.
In a series of 10 patients 10 in stage A0, AI, AII and B at diagnosis, a decrease in lymphocyte counts and palpable lymph nodes and spleen was observed in the absence of treatment after a median follow-up of 9 years (range 4-21). Six of the 10 cases showed a clinical remission defined as complete absence of anemia or thrombocytopenia, lymphadenopathy, splenomegaly or constitutional symptoms and a lymphocyte count <4 x 10 9 /L. No BM assessment was performed and there was evidence of persistence of the CLL clone in most cases, with 1 to 50% of circulating CLL cells. In other 3 recent cases of spontaneous CLL regression, a clonal remission was documented by immunophenotype in both PB and BM in 2 cases 9, 11 , and molecularly in the PB with evidence of residual disease in the marrow in the third case 8 .
No concomitant clinical conditions that may lead to a spontaneous regression of CLL have been clearly identified, though antihypertensive therapy with the calcium antagonist verapamil has been associated to some of these cases 18 . More recently, it has been reported that intake of green tea products may induce regression of low-grade B-cell malignancies, including CLL 19 . A spontaneous remission of CLL can also precede the diagnosis of a primary second malignancy by months or years 20, 21 .
We add to the literature with a series of 9 cases managed over the years at a single Institution, in which the occurrence of a spontaneous regression of CLL occurred after a The CLL clone was still immunophenotypically evident in the PB, ranging from 3 to 60% (median 44%) of circulating lymphocytes. The expression of CD38 and of ZAP-70 on CLL cells was, as expected, always negative. The IgVH genes were mutated in all cases, whilst the IgVL genes were mutated in 75% of them. Interestingly, there was an evident restriction in the IgVH family usage, with the VH3 family represented in all cases but 1.
Two out of 7 (30%) showed the usage of the VH3-30 gene. The VH3 family is one of the most represented in both mutated and unmutated CLL 22, 23 and the VH3-30 gene comprises about 7% of all CLL cases 22, 23 . However, comparing a series of stable (n=78) and progressive (n=74) CLL from our Institute, VH3-30 was significantly overrepresented in patients with stable (n=10, all mutated) rather than with progressive disease (n=1, unmutated) (p 0.0006) (personal data); thus, VH3-30 might be suggested as a marker of very indolent disease. The Ig light chain genes represented among CLL in spontaneous regression were Vk4-1, Vk2-30, Vk3-15, Vλ1-51, Vλ2-11, Vλ1-47. The Vk4-1 and Vk2-30 are frequently represented in unselected CLL 23 , being the third and fourth most common κ chain genes, respectively. Vλ1-51 and Vλ2-11 genes also recur, each representing about 5% of all λ light chain genes, though reported as mostly unmutated. We previously reported on a series of 25 highly stable and indolent CLL patients who never required treatment over a prolonged follow-up period 6 . In that series, the IgVH and IgV L genes were mostly mutated and a biased IgVH usage was highlighted, with a preferential usage of VH3 (40%) and VH4 (20%) families, and VH3-72 (24%) and VH2-05 (12%) genes. Among
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From IgV L genes, V k 1-5 (36%) and V k 4-1 (13%) were the most represented. An association between V k 4-1 and VH3-72 was recorded. Also in our series of spontaneous regressing cases, the usage of the Vk4-1 gene occurred. However, we did not find recurrent associations between heavy and light chain genes nor characteristic HCDR3/LCDR3 aminoacidic motifs.
Specific features in the gene machinery of the CLL clone in regression were identified.
Microarray analysis revealed a distinctive pattern of expression for such cases both by
unsupervised and supervised approaches. The most intriguing and somehow unexpected finding comes from the overrepresentation of several BCR-related genes, suggesting that the BCR signaling may play an important role in the spontaneous regression scenario.
These findings are supported by the recent paper reporting that in IgVH mutated CLL IgM stimulation induces an apoptotic signal 24 . Another hypothesis could be that in these patients the BCR signaling cascade is simply intact, indicating that the B-cell is properly functioning as antigen presenting cell. This possibility is further supported by two evidences: first, β 2M, the β chain of the HLA class I complex, is highly expressed in these cases, in line with the fact that -in solid tumors -its lack induces a mechanism of tumor escape from cytotoxic lymphocyte recognition; second, the analysis of T-cell response in these patients reveals a closer similarity of their profile of cytokine expression with that of T-cells from healthy donors. Furthermore, in agreement with a previous report by Durig et al. 15 , in the spontaneous regression cases we documented an upregulation of β 2M and CCNI, as well as an upregulation of ribosomal genes, thus confirming the impact of the translation-associated genes, in particular ribosomal genes, on the clinical behavior.
Finally, given that microRNAs (miRs) appear to play a key role in CLL initiation and/or progression, the overexpression of DICER in spontaneous regression and stable disease cases is intriguing, since this gene is a regulator of miRs processing. These tiny RNA For personal use only. on October 3, 2017. by guest www.bloodjournal.org From molecules repress the expression of several target genes; downregulation of DICER in progressive patients suggests that this mechanism of gene repression is impaired.
Comparison between CLL cases and B lymphocytes from normal donors has highlighted a
higher degree of similarity of the latter with cases in spontaneous regression rather than with the remaining CLL patients. Of interest, β 2M and CCNI were overexpressed also in normal B lymphocytes, as well as DICER, thus corroborating the hypothesis that β 2M downregulation is associated with disease progression and that downregulation of DICER may be involved in tumor progression, as reported in lung cancer patients 25 . Among the genes that were discordant between CLL in spontaneous regression and normal B lymphocytes, SYK, a tyrosine kinase involved in BCR signaling and known to play a role in CLL pathogenesis, is more highly expressed in regression cases, suggesting that this molecule may contribute to the persistence of the malignant clone. 
